Open AccessPharmacokinetic analysis of gefitinib in a patient with advanced non‐small cell lung cancer undergoing hemodialysis
Author(s) -
Luo Jinmei,
Ni Li,
Wang Mengzhao,
Zhong Wei,
Xiao Yi,
Zheng Ke,
Hu Pei
Publication year - 2016
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.12263
Subject(s) - gefitinib , medicine , hemodialysis , pharmacokinetics , lung cancer , oncology , chemotherapy , cancer , epidermal growth factor receptor
Patients undergoing hemodialysis (HD) are frequently elderly with poor performance status and usually cannot withstand chemotherapy because of its toxicities. We report a case of an elderly woman with chronic renal failure undergoing HD who was diagnosed with advanced non‐small cell lung cancer and treated with orally administered gefitinib. We analyzed the pharmacokinetic data of gefitinib in this patient and found that that gefitinib was safe under these conditions.